Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

Dabbous et al., Scientific Reports, doi:10.1038/s41598-021-85227-0 (date from preprint)
Sep 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
This paper has been retracted
Dabbous et al., 29 Sep 2020, peer-reviewed, 11 authors.
This PaperHCQAll
RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
Hany M Dabbous, Manal H El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F S Ebeid, Ahmed F Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M Hassany, Ahmed R Riad, Mohamed A Tageldin
Scientific Reports, doi:10.1038/s41598-021-85227-0
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2-day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2-10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQarm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients. At the end of 2019, the entire world saw the first appearance of the coronavirus disease 2019 (COVID-19) 1 . By March 2020, it was declared a pandemic by the World Health Organization (WHO). Globally, more than 83 million cases of COVID-19 and more than 1.5 million deaths have been reported so far 2, 3 . The first case registered in Egypt was in February 2020, and, since then, the number has been increasing. By early July 2020, nearly 1.5 hundred thousand confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and about 8000 deaths were reported by the Ministry of Health (MoH) 4 . In Egypt, the curve of new cases prompted an investigation into the different treatment options to find the most effective and safe choice for COVID-19 patients. Favipiravir (FPV) is one of the potential options according to a Chinese study, considering its past history of efficacy against viral influenza 5 . Being a novel RNA-dependent RNA polymerase (RdRp) inhibitor, FPV has also shown efficacy against the Ebola virus 6, 7 . FVP, known as Avigan, is a pyrazine derivative and guanine analogue that acts as a chain termination tool and prevents RNA elongation. Favipiravir demonstrated anti-viral activities against a broad array of RNA viruses, including arenaviruses, bunyaviruses, and filoviruses 8 . In Japan, favipiravir has been approved for influenza A resistant to neuraminidase inhibitors 9 . Also, an expert consensus group in China suggested that chloroquine improved lung imaging and shortened the disease course 10 . However, a number of additional reports have since shown no positive..
Author contributions H.D. shared in the protocol of the study, data collection and writing the manuscript. A.F.S. data collection and writing the manuscript. All other authors contributed equally in Management and follow up of patients beside data collection. By M.E. statistical analysis was done. Study design and revision of the manuscript by M.E.-S. and F.E. were done. R E T R A C T E D A R T I C L E Competing interests The authors declare no competing interests.
Borba, Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study), JAMA Netw. Open, doi:10.1001/jamanetworkopen.2020.8857
Bosaeed, A trial of favipiravir and hydroxychloroquine combination in adults hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial, Trials, doi:10.1186/s13063-020-04825-x.PMID:33129363;PMCID:PMC7602769
Cai, Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering
Chan, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet
Chen, Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial, doi:10.1101/2020.03.22.20040758v3
Chen, Zhang, Huang, Yin, Favipiravir versus arbidol for COVID-19: A randomized clinical trial, doi:10.1101/2020.03.17.20037432v4
De Barros, COVID-19 pandemic-A narrative review of the potential roles of chloroquine and hydroxychloroquine, Pain Physician
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends
Geleris, Sun, Platt, Zucker, Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N. Engl. J. Med
Hayden, Shindo, Influenza virus polymerase inhibitors in clinical development, Curr. Opin. Infect. Dis
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jun, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J. Zhejiang Univ
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Madelain, Ebola virus dynamics in mice treated with favipiravir, Antiviral Res
Magagnoli, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19, doi:10.1101/2020.04.16.20065920v1.full.pdf
Mahevas, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: Results of a study using routinely collected data to emulate a target trial, BMJ
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir-A potential treatment in the COVID-19 pandemic?, J. Virus Erad
Saber-Ayad, Saleh, Abu-Gharbieh, The rationale for potential pharmacotherapy of COVID-19, Pharmaceuticals
Tang, Hydroxychloroquine in patients mainly with mild to moderate COVID-19: An open-label, randomized, controlled trial, doi:10.1101/2020.04.10.20060558v2
Tang, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial, BMJ
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Zhonghua, He, Hu, Za, Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study [published correction appears in, Lancet
Zhou, Dai, Tong, COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop